A Phase II Trial Of Oral Bicalutamide With Subcutaneous Goserelin In Patients With Epithelial Ovarian, Fallopian Tube, Or Peritoneal Carcinoma In Second Or Greater Remission
OBJECTIVES: I. Determine the time-to-treatment failure in patients with ovarian epithelial,
fallopian tube, or peritoneal carcinoma, in second or greater remission, treated with
bicalutamide and goserelin. II. Assess luteinizing hormone and follicle-stimulating hormone
suppression in correlation with serum vascular endothelial growth factor levels, and
determine if these levels are related to time to treatment failure in these patients. III.
Correlate the presence or absence of androgen receptor tissue expression by
immunohistochemistry and androgen receptor gene trinucleotide repeat length to time to
treatment failure in these patients.
OUTLINE: Patients receive oral bicalutamide once daily and goserelin subcutaneously once
every 4 weeks. Treatment continues in the absence of unacceptable toxicity until disease
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Primary Purpose: Treatment
Paul Sabbatini, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center
|New York, New York 10021